| NCT05891964 | Jinnah Postgraduate Medical Centre | Plaque Psoriasis | 2021-07-05 | PHASE4 |
| NCT02394561 | Novartis Pharmaceuticals | Plaque Type Psorisis | 2015-04-10 | PHASE3 |
| NCT03791060 | Beth Israel Deaconess Medical Center|Novartis Pharmaceuticals | Necrobiosis Lipoidica Diabeticorum | 2019-04-03 | PHASE2 |
| NCT01539213 | Novartis Pharmaceuticals | Healthy|Psoriasis | 2012-02 | PHASE1 |
| NCT02748863 | Novartis Pharmaceuticals | Psoriasis | 2016-12-12 | PHASE3 |
| NCT04488185 | Novartis Pharmaceuticals | Psoriasis | 2020-11-02 | PHASE4 |
| NCT04239859 | Singapore General Hospital|Translational Immunology Institute | Plaque Psoriasis | 2024-01 | PHASE4 |
| NCT03478787 | AbbVie | Psoriasis | 2018-05-08 | PHASE3 |
| NCT02721966 | Novartis Pharmaceuticals | Axial Psoratic Arthritis | 2016-10-03 | PHASE3 |
| NCT06130540 | Novartis Pharmaceuticals | Giant Cell Arteritis|Polymyalgia Rheumatica | 2024-03-27 | PHASE1 |
| NCT05080218 | Jeffrey Curtis|University of Alabama at Birmingham|University of Nebraska|University of Pennsylvania|AbbVie|Bristol-Myers Squibb|Novartis|Eli Lilly and Company|Pfizer|Illumination Health | Rheumatoid Arthritis|Psoriatic Arthritis|Spondylarthritis | 2021-11-15 | PHASE4 |
| NCT02474082 | Novartis Pharmaceuticals | Psoriasis | 2015-04 | PHASE3 |
| NCT04300296 | Novartis Pharmaceuticals | Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris | 2020-07-27 | PHASE2 |
| NCT04930094 | Novartis Pharmaceuticals | Giant Cell Arteritis (GCA) | 2021-10-06 | PHASE3 |
| NCT07151508 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Neterton Syndrome | 2023-12-19 | |
| NCT01892436 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2013-09-30 | PHASE3 |
| NCT05344482 | Novartis Pharmaceuticals | Plaque Psoriasis | 2020-07-09 | |
| NCT02896127 | Novartis Pharmaceuticals | Ankylosing Spondyloarthritis | 2016-10-18 | PHASE3 |
| NCT01377012 | Novartis Pharmaceuticals | Rheumatoid Arthritis | 2011-08-30 | PHASE3 |
| NCT02159053 | Novartis Pharmaceuticals | Spondylitis, Ankylosing | 2015-05-18 | PHASE3 |
| NCT04996485 | National Medical Research Center for Children´s Health, Russian Federation | Congenital Ichthyosis | 2021-03-01 | PHASE4 |
| NCT01250171 | Novartis Pharmaceuticals | Dry Eye | 2010-11 | PHASE2 |
| NCT07485764 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Psoriasis|Plaque Psoriasis|Moderate-to-severe Plaque Psoriasis|Overweight , Obesity | 2026-06 | PHASE4 |
| NCT02008890 | Novartis Pharmaceuticals | Palmoplantar Pustular Psoriasis | 2013-12-26 | PHASE3 |
| NCT02294227 | Novartis Pharmaceuticals | Arthritis, Psoriatic | 2015-05-29 | PHASE3 |
| NCT02662985 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2016-08-22 | PHASE3 |
| NCT04403243 | Lomonosov Moscow State University Medical Research and Educational Center | COVID 19 | 2020-05-08 | PHASE2 |
| NCT02483234 | University of Erlangen-Nürnberg Medical School | Psoriasis|Psoriatic Arthritis | 2015-05-31 | PHASE2 |
| NCT06331312 | Novartis Pharmaceuticals | Polymyalgia Rheumatica | 2024-06-28 | PHASE3 |
| NCT01952015 | Novartis Pharmaceuticals | Psoriasis | 2013-08-21 | PHASE3 |
| NCT02826603 | Novartis Pharmaceuticals | Plaque Psoriasis | 2016-06-22 | PHASE3 |
| NCT03589885 | Novartis Pharmaceuticals | Plaque Psoriasis | 2018-12-19 | PHASE3 |
| NCT03350815 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2018-03-13 | PHASE4 |
| NCT06833112 | The Affiliated Hospital Of Guizhou Medical University | Ankylosing Spondylitis | 2025-02 | PHASE4 |
| NCT03713619 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2019-01-31 | PHASE3 |
| NCT05767034 | Novartis Pharmaceuticals | Polymyalgia Rheumatica | 2023-03-22 | PHASE3 |
| NCT02547714 | Novartis Pharmaceuticals | Plaque Psoriasis | 2015-06-16 | PHASE4 |
| NCT05368818 | Novartis Pharmaceuticals | Plaque Psoriasis | 2020-12-07 | |
| NCT06751238 | Novartis Pharmaceuticals | Juvenile Psoriatic Arthritis | 2025-09-24 | PHASE1 |
| NCT04737330 | Novartis Pharmaceuticals | Thyroid Eye Disease|Graves Orbitopathy | 2021-11-29 | PHASE3 |
| NCT06786936 | NHS Greater Glasgow and Clyde|University of Glasgow|Medical Research Council | Psoriatic Arthritis|Depression|Psoriatic Plaque | 2025-06-02 | |
| NCT02733094 | Technical University of Munich|Novartis | Pyoderma Gangrenosum | 2016-04 | PHASE1|PHASE2 |
| NCT06444087 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2024-06-17 | |
| NCT04274166 | Wake Forest University Health Sciences|Novartis | Pyoderma Gangrenosum | 2021-05 | PHASE2 |
| NCT02008916 | Novartis Pharmaceuticals | Spondylitis, Ankylosing | 2014-01-14 | PHASE3 |
| NCT05676333 | University Hospital, Ghent|Novartis | Vitiligo|Secukinumab | 2016-10-12 | PHASE4 |
| NCT03149900 | Diamant Thaci|Novartis | Psoriasis Vulgaris | 2016-10 | |
| NCT01392326 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2011-09 | PHASE3 |
| NCT02144857 | University of Athens | Psoriasis | 2014-05-30 | PHASE4 |
| NCT02690701 | Novartis Pharmaceuticals | Chronic Plaque Psoriasis | 2016-02-10 | PHASE4 |
| NCT07261072 | Peking Union Medical College | Hidradenitis Suppurativa (HS)|Hidradenitis Suppurativa (Acne Inversa)|Secukinumab | 2025-12-01 | PHASE4 |
| NCT07352566 | University of California, San Francisco | Psoriasis|Atopic Dermatitis | 2026-01-01 | PHASE4 |
| NCT03713632 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2019-02-25 | PHASE3 |
| NCT02044848 | Novartis Pharmaceuticals | Type 1 Diabetes Mellitus | 2014-02 | PHASE2 |
| NCT02763046 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2016-05-31 | PHASE4 |
| NCT03568136 | GWT-TUD GmbH|Novartis Pharmaceuticals | Dermatitis, Atopic|Eczema, Atopic|Neurodermatitis, Atopic | 2018-09-18 | PHASE2 |
| NCT05527444 | Qilu Hospital of Shandong University | Ankylosing Spondylitis | 2022-03-15 | PHASE4 |
| NCT03358134 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Novartis | Spondylarthropathies | 2014-03 | PHASE3 |
| NCT01649375 | Novartis Pharmaceuticals | Anklyosing Spondylitis | 2012-10-18 | PHASE3 |
| NCT01544595 | Novartis Pharmaceuticals | Moderate to Severe Plaque-type Psoriasis | 2012-06-19 | PHASE3 |
| NCT02594098 | Icahn School of Medicine at Mount Sinai|Novartis | Atopic Dermatitis | 2015-11 | PHASE2 |
| NCT04711902 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2021-06-24 | PHASE3 |
| NCT02559622 | Novartis Pharmaceuticals | Psoriasis | 2014-04 | PHASE3 |
| NCT03384745 | Bond Avillion 2 Development LP|Avillion LLP | Psoriasis | 2018-07-31 | PHASE2 |
| NCT01807520 | Novartis Pharmaceuticals | Moderate to Severe Nail Psoriasis | 2013-06-20 | PHASE3 |
| NCT07477795 | Assistance Publique - H?pitaux de Paris | Takayasu Arteritis|Large Vessel Vasculitis | 2026-04-01 | PHASE2 |
| NCT05622708 | Novartis Pharmaceuticals | Non-radiographic Axial Spondyloarthritis | 2023-03-28 | PHASE4 |
| NCT03344640 | Novartis Pharmaceuticals | Tendinopathy | 2017-12-15 | PHASE2 |
| NCT06707246 | Second Affiliated Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Wenzhou Medical University|Jinhua Central Hospital|Affiliated Hospital of Jiaxing University|Ningbo No. 1 Hospital|The First People´s Hospital of Huzhou | Hidradenitis Suppurativa | 2024-12-15 | NA |
| NCT03307447 | Narrows Institute for Biomedical Research|Novartis | Psoriasis Vulgaris | 2017-12-19 | PHASE4 |
| NCT01636687 | Novartis Pharmaceuticals | Plaque-type Psoriasis | 2012-10-17 | PHASE3 |
| NCT01989468 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2014-04-10 | PHASE3 |
| NCT05320159 | Novartis Pharmaceuticals | Psoriasis | 2021-02-03 | |
| NCT03445845 | Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France | Axial Spondyloarthritis | 2018-12-14 | PHASE4 |
| NCT05722522 | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 2023-08-10 | PHASE3 |
| NCT01770379 | Novartis Pharmaceuticals | Rheumatoid Arthritis | 2012-10 | PHASE3 |
| NCT04717466 | University of Miami|Novartis | Psoriasis|Healthy | 2021-06-29 | PHASE4 |
| NCT01478360 | Novartis Pharmaceuticals | Asthma | 2012-03 | PHASE2 |
| NCT04894890 | Novartis Pharmaceuticals | Psoriasis | 2021-09-26 | |
| NCT02771210 | Novartis Pharmaceuticals | Psoriatic Arthritis|Axial Spondyloarthritis|Enthesitis | 2016-08-30 | PHASE3 |
| NCT03828643 | Universita di Verona | Psoriasis Vulgaris | 2019-03-20 | |
| NCT03668613 | Novartis Pharmaceuticals | Moderate to Severe Chronic Plaque-type Psoriasis | 2018-08-29 | PHASE3 |
| NCT06517732 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2024-07-26 | |
| NCT03536884 | UCB Biopharma SRL | Chronic Plaque Psoriasis|Moderate to Severe Chronic Plaque Psoriasis | 2018-06-13 | PHASE3 |
| NCT06398652 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 2024-08-27 | PHASE3 |
| NCT05758415 | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 2023-08-02 | PHASE3 |
| NCT03099980 | Tufts Medical Center | Hidradenitis Suppurativa | 2016-07-11 | EARLY_PHASE1 |
| NCT06142357 | Novartis Pharmaceuticals | Moderate-to-severe Plaque Psoriasis | 2023-12-29 | |
| NCT06431750 | Novartis Pharmaceuticals | Juvenile Idiopathic Arthritis | 2025-04-30 | |
| NCT05303285 | Tongji Hospital|Wuhan Central Hospital|Wuhan Hospital of Traditional Chinese Medicine|Novartis|Johns Hopkins Bloomberg School of Public Health | Ankylosing Spondylitis (AS) | 2024-06-14 | PHASE4 |
| NCT07138898 | NYU Langone Health | Rheumatic Disease | 2025-09 | PHASE2 |
| NCT04181762 | Novartis Pharmaceuticals | Lupus Nephritis | 2020-07-07 | PHASE3 |
| NCT07109765 | Peking Union Medical College | Hidradenitis Suppurativa (HS) | 2025-06-01 | |
| NCT03955861 | Belfast Health and Social Care Trust|British Medical Association|Psoriasis and Psoriatic Arthritis Alliance|Queen´s University, Belfast | Psoriatic Arthritis|Psoriasis|Enthesitis | 2019-02-14 | |
| NCT03769168 | Novartis Pharmaceuticals | Juvenile Psoriatic Arthritis|Enthesitis Related Arthritis | 2019-06-07 | PHASE3 |
| NCT06926192 | Peking Union Medical College | Hidradenitis Suppurativa (HS)|Hidradenitis Suppurativa (Acne Inversa)|Secukinumab | 2020-01-01 | |
| NCT05650060 | Novartis Pharmaceuticals | Plaque Psoriasis | 2021-01-20 | |
| NCT04887597 | University of Erlangen-Nürnberg Medical School | Psoriatic Arthritis|Enthesitis|Biopsy | 2019-03-18 | PHASE4 |
| NCT06905288 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2025-04-02 | |
| NCT05232864 | Novartis Pharmaceuticals | Lupus Nephritis | 2022-08-22 | PHASE3 |
| NCT01863732 | Novartis Pharmaceuticals | Spondylitis, Ankylosing | 2013-11-06 | PHASE3 |
| NCT06398106 | University Hospital, Ghent|Belgium Health Care Knowledge Centre | Psoriasis Vulgaris | 2024-12-20 | PHASE4 |
| NCT05513014 | Novartis Pharmaceuticals | Psoriasis | 2021-03-21 | |
| NCT04535999 | University of Pennsylvania|Novartis | Psoriasis | 2022-02-07 | PHASE4 |
| NCT02798211 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2016-06-27 | PHASE4 |
| NCT04179175 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2020-03-18 | PHASE3 |
| NCT07243782 | Novartis Pharmaceuticals | Hidradenitis Suppurativa|Pediatric Plaque Psoriasis|Juvenile Idiopathic Arthritis | 2025-12-22 | |
| NCT04340076 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Belgium Health Care Knowledge Centre|University Hospital, Ghent | Psoriasis|Psoriasis Vulgaris | 2020-08-20 | PHASE4 |
| NCT04732117 | Novartis Pharmaceuticals | Non-radiographic Axial Spondyloarthritis | 2021-07-21 | PHASE3 |
| NCT03031782 | Novartis Pharmaceuticals | Juvenile Psoriatic Arthritis|Enthesitis-related Arthritis | 2017-05-23 | PHASE3 |
| NCT01359943 | Novartis Pharmaceuticals | Rheumatoid Arthritis | 2011-10 | PHASE2 |
| NCT02362789 | Novartis Pharmaceuticals | Psoriasis | 2015-01-04 | PHASE3 |
| NCT02752776 | Novartis Pharmaceuticals | Plaque Psoriasis | 2016-03-17 | PHASE4 |
| NCT02404350 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2015-08-31 | PHASE3 |
| NCT02471144 | Novartis Pharmaceuticals | Chronic Severe Plaque-type Psoriasis | 2015-09-29 | PHASE3 |
| NCT04237116 | Novartis Pharmaceuticals | Plaque Psoriasis|Non-alcoholic Fatty Liver Disease | 2020-02-19 | PHASE3 |
| NCT04638647 | Novartis Pharmaceuticals | Autoimmunity, Inflammation | 2020-12-22 | PHASE4 |
| NCT05569174 | Novartis Pharmaceuticals | Tendinopathy | 2022-12-02 | PHASE3 |
| NCT01555125 | Novartis Pharmaceuticals | Moderate to Severe Plaque-type Psoriasis | 2012-05-08 | PHASE3 |
| NCT05921994 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2023-08-10 | |
| NCT02267135 | Novartis Pharmaceuticals | Chronic Scalp Psoriasis | 2014-09-29 | PHASE3 |
| NCT06945107 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Plaque Psoriasis | 2025-05-27 | PHASE3 |
| NCT04632927 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2020-12-21 | PHASE3 |
| NCT03866317 | Massachusetts General Hospital|Novartis | Discoid Lupus Erythematosus | 2019-09-01 | PHASE2 |
| NCT02778711 | Tanja Todberg, MD | Allergic Contact Dermatitits | 2016-01 | PHASE3 |
| NCT05155098 | Novartis Pharmaceuticals | Moderate to Severe Plaque Psoriasis|Psoriatic Arthritis|Ankylosing Spondylitis|Non-radiographic Axial Spondyloarthritis | 2022-03-25 | |
| NCT01752634 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2013-04-14 | PHASE3 |
| NCT03079531 | Anne Chang | Papulopustular Rosacea | 2017-06-21 | PHASE1|PHASE2 |
| NCT04156620 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2019-12-11 | PHASE3 |
| NCT02745080 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2017-04-03 | PHASE3 |
| NCT05380453 | Novartis Pharmaceuticals | Giant Cell Arteritis | 2022-09-29 | PHASE3 |
| NCT01358175 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2011-10 | PHASE3 |
| NCT02409667 | Novartis Pharmaceuticals | Plaque Psoriasis | 2015-05-07 | PHASE3 |
| NCT02750592 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2016-03-22 | PHASE3 |
| NCT03066609 | Novartis Pharmaceuticals | Plaque Psoriasis | 2017-02-28 | PHASE3 |
| NCT01412944 | Novartis Pharmaceuticals | Plaque-type Psoriasis | 2011-12 | PHASE3 |
| NCT03504852 | Novartis Pharmaceuticals | Moderate to Severe Chronic Plaque-type Psoriasis | 2018-06-25 | PHASE3 |
| NCT01358578 | Novartis Pharmaceuticals | Chronic Plaque Psoriasis | 2011-06 | PHASE3 |
| NCT04610476 | University of Erlangen-Nürnberg Medical School | Psoriatic Arthritis|Withdrawal|Reduction | 2020-10-19 | PHASE3 |
| NCT06785675 | Novartis Pharmaceuticals | Hidradenitis Suppurativa | 2025-03-10 | |
| NCT03623867 | Chinese University of Hong Kong | Psoriatic Arthritis | 2020-05-18 | PHASE4 |
| NCT02599129 | Icahn School of Medicine at Mount Sinai|Novartis | Alopecia Areata | 2015-11 | PHASE2 |
| NCT07254325 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 2025-12-15 | PHASE1 |
| NCT03440736 | Novartis Pharmaceuticals | Psoriasis|Metabolic Syndrome | 2018-02-28 | PHASE4 |
| NCT03131570 | James G. Krueger, MD, PhD|Novartis | Psoriasis | 2017-05-23 | PHASE2 |
| NCT04469829 | Universita di Verona | Psoriasis|Metabolic Syndrome | 2020-08-01 | PHASE4 |
| NCT03535194 | Eli Lilly and Company | Psoriasis | 2018-06-26 | PHASE3 |
| NCT07190053 | Novartis Pharmaceuticals | Enthesitis-related Arthritis (ERA)|Juvenile Psoriatic Arthritis (JPsA) | 2025-12 | |
| NCT02854163 | University of Liverpool|Novartis | Psoriatic Arthritis | 2016-10-15 | PHASE2 |
| NCT03639740 | Professor Mikkel ?stergaard|Novartis Healthcare A+S | Axial Spondyloarthritis|Ankylosing Spondylitis | 2019-01-15 | PHASE4 |
| NCT04571567 | Saakshi Khattri | Psoriasis | 2019-12-02 | PHASE4 |
| NCT01537432 | Novartis Pharmaceuticals | Psoriasis, Plaque-type Psoriasis | 2012-01 | PHASE2 |
| NCT03055494 | Novartis Pharmaceuticals | Plaque Psoriasis | 2017-04-18 | PHASE4 |
| NCT03020199 | Novartis Pharmaceuticals | Plaque Psoriasis | 2017-03-27 | PHASE4 |
| NCT02595970 | Novartis Pharmaceuticals | Psoriasis | 2015-05-20 | PHASE3 |
| NCT03765788 | Novartis Pharmaceuticals | Giant Cell Arteritis | 2019-01-30 | PHASE2 |
| NCT07489573 | Novartis Pharmaceuticals | Hidradenitis Suppurativa (HS) | 2026-08-21 | PHASE4 |
| NCT05206591 | Novartis Pharmaceuticals | Active Peripheral Spondyloarthritis (pSpA) | 2022-08-16 | PHASE3 |
| NCT04967950 | Peking Union Medical College Hospital | Psoriatic Arthritis | 2021-07-15 | PHASE1 |
| NCT05677542 | Novartis Pharmaceuticals | Axial Spondyloarthritis|Psoriatic Arthritis | 2021-06-02 | |
| NCT01828086 | Novartis Pharmaceuticals | Chronic Plaque-type Psoriasis | 2013-06 | PHASE1 |
| NCT07237594 | Duke University | Metastatic Melanoma | 2026-05-01 | PHASE1 |
| NCT06600009 | Novartis | Psoriatic Arthritis | 2022-10-17 | |
| NCT05734482 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Psoriasis | 2023-02-15 | PHASE1 |
| NCT06110676 | Livzon Pharmaceutical Group Inc. | Psoriasis | 2023-08-21 | PHASE3 |
| NCT05583604 | Novartis Pharmaceuticals | Hidradenitis Suppurativa (HS) | | |
| NCT01806597 | Novartis Pharmaceuticals | Moderate to Severe Palmoplantar Psoriasis | 2013-06-19 | PHASE3 |
| NCT02074982 | Novartis Pharmaceuticals | Chronic Plaque Type Psoriasis | 2014-02-26 | PHASE3 |
| NCT03041038 | Northwestern University|Icahn School of Medicine at Mount Sinai | Ichthyosis|Autosomal Recessive Congenital Ichthyosis|Lamellar Ichthyosis|Congenital Ichthyosiform Erythroderma|Epidermolytic Ichthyosis|Netherton Syndrome | 2016-12 | PHASE2 |
| NCT01365455 | Novartis Pharmaceuticals | Moderate to Severe Plaque-type Psoriasis | 2011-06 | PHASE3 |
| NCT04414605 | Guangdong Provincial Hospital of Traditional Chinese Medicine | Psoriasis | 2020-06-04 | EARLY_PHASE1 |
| NCT05503875 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Immunoclassification|Psoriasis | 2023-01-01 | NA |
| NCT02696031 | Novartis Pharmaceuticals | Non-radiographic Spondyloarthritis | 2016-04-29 | PHASE3 |
| NCT03090100 | Janssen Research & Development, LLC | Psoriasis | 2017-04-27 | PHASE3 |
| NCT02474069 | Novartis Pharmaceuticals | Moderate to Severe Plaque-type Psoriasis | 2015-02-08 | PHASE3 |
| NCT01095250 | Novartis Pharmaceuticals | Uveitis | 2010-04 | PHASE3 |
| NCT01093846 | Novartis Pharmaceuticals | Uveitis | 2010-03 | PHASE3 |
| NCT00809614 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2009-03 | PHASE2 |
| NCT00770965 | Novartis Pharmaceuticals | Chronic Plaque Psoriasis | 2008-09-10 | PHASE2 |
| NCT04209205 | Novartis Pharmaceuticals | Psoriatic Arthritis | 2020-01-29 | PHASE3 |
| NCT01640951 | Novartis Pharmaceuticals | Moderate to Severe Chronic Plaque-Type Psoriasis | 2012-09-16 | PHASE3 |
| NCT00941031 | Novartis Pharmaceuticals | Chronic Plaque-type Psoriasis | 2009-07 | PHASE2 |
| NCT02911857 | Novartis Pharmaceuticals | Periodic Fevers Syndrome | 2016-10-03 | PHASE3 |
| NCT01103024 | Novartis | Uveitis | 2010-12 | PHASE3 |
| NCT01364389 | Novartis Pharmaceuticals | Polymyalgia Rheumatica|Inflammatory Diseases | 2011-02-14 | PHASE2 |
| NCT03259074 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2017-11-30 | PHASE3 |
| NCT00920933 | Novartis Pharmaceuticals | Healthy | 2009-01 | PHASE1|PHASE2 |
| NCT01032915 | Novartis Pharmaceuticals | Non-infectious Uveitis | 2010-02 | PHASE3 |
| NCT02607774 | Novartis Pharmaceuticals | Moderate to Severe Plaque Psoriasis | 2015-12-17 | PHASE1 |
| NCT00685399 | Novartis Pharmaceuticals | Non-infectious Uveitis | 2008-06 | PHASE2 |
| NCT01406938 | Novartis Pharmaceuticals | Moderate to Severe Plaque-type Psoriasis | 2011-08 | PHASE3 |
| NCT01090310 | Novartis Pharmaceuticals | Non-infectious Uveitis | 2010-08 | PHASE3 |
| NCT01874340 | Novartis Pharmaceuticals | Multiple Sclerosis | 2013-06 | PHASE2 |
| NCT01071252 | Novartis Pharmaceuticals | Chronic Plaque-type Psoriasis | 2010-03 | PHASE2 |
| NCT00809159 | Novartis Pharmaceuticals | Ankylosing Spondylitis | 2009-03 | PHASE2 |
| NCT00805480 | Novartis Pharmaceuticals | Chronic Plaque Psoriasis | 2008-12 | PHASE2 |
| NCT00584740 | Novartis Pharmaceuticals | Crohn´s Disease | 2008-08 | PHASE2 |
| NCT03136861 | Novartis Pharmaceuticals | Spondyloarthritis | 2017-06-30 | PHASE3 |
| NCT00669916 | Novartis Pharmaceuticals | Plaque Psoriasis | 2007-02 | PHASE1|PHASE2 |
| NCT00995709 | Novartis Pharmaceuticals | Behcet Disease | 2009-10 | PHASE3 |
| NCT01132612 | Novartis Pharmaceuticals | Plaque-type Psoriasis | 2010-05-11 | PHASE2 |
| NCT01051817 | Novartis Pharmaceuticals | Relapsing-remitting Multiple Sclerosis|RRMS | 2009-12 | PHASE2 |
| NCT01433250 | Novartis Pharmaceuticals | Multiple Sclerosis | 2012-02 | PHASE2 |
| NCT01327664 | Novartis Pharmaceuticals | Uveitis | 2011-03 | PHASE3 |
| NCT01009281 | Novartis Pharmaceuticals | Crohn´s Disease|Inflammatory Bowel Disease | 2009-10-30 | PHASE2 |
| NCT00669942 | Novartis Pharmaceuticals | Rheumatoid Arthritis | 2005-12 | PHASE1|PHASE2 |
| NCT01350804 | Novartis Pharmaceuticals | Rheumatoid Arthritis | 2011-09 | PHASE3 |
| NCT04298320 | Yanqiao Zhang | Colorectal Cancer | 2020-03-15 | PHASE1|PHASE2 |